Deya Corzo

Deya Corzo is Chief Medical Officer-in-residence at Roivant Sciences. Deya is an expert in drug development, clinical genetics and rare diseases with over two decades of experience in the biotechnology sector. Prior industry experience includes roles as Chief Medical Officer at Sigilon Therapeutics and Sojournix Inc., and senior R&D positions at uniQure and Genzyme Corporation overseeing clinical development programs for rare diseases. Deya is a practicing, board-certified clinical geneticists and pediatrician, as well as a faculty member at Harvard Medical School where she completed postdoctoral research and clinical training.